argenx SE - American Depositary Shares (NQ:ARGX)

882.48 +13.15 (+1.51%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...

Via Finterra

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

February 26, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis

February 26, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at TD Cowen 46th Annual Healthcare Conference

February 23, 2026

From argenx SE

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

February 19, 2026

From argenx SE

Via GlobeNewswire

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

Via The Motley Fool

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

January 13, 2026

From argenx SE

Via GlobeNewswire

argenx Highlights 2026 Strategic Priorities

January 12, 2026

From argenx SE

Via GlobeNewswire

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From argenx SE

Via GlobeNewswire

argenx Announces Leadership Transition Marking Next Evolution of Growth

January 05, 2026

From argenx SE

Via GlobeNewswire

Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth

January 02, 2026

As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...

Via MarketMinute

Topics Artificial Intelligence Economy

The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy

December 31, 2025

As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology

December 26, 2025

As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...

Via PredictStreet

Topics Economy Intellectual Property

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease

December 15, 2025

From argenx SE

Via GlobeNewswire

ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth ↗

December 01, 2025

ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

November 18, 2025

Via Benzinga

argenx Announces Results of Extraordinary General Meeting of Shareholders

November 18, 2025

From argenx SE

Via GlobeNewswire

Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules ↗

November 14, 2025

Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow.

Via Chartmill

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

November 05, 2025

Via Benzinga

Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗

October 30, 2025

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

Via Investor's Business Daily

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

October 30, 2025

From argenx SE

Via GlobeNewswire

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients

October 29, 2025

From argenx SE

Via GlobeNewswire

ARGENX SE - ADR (NASDAQ:ARGX) Shows Strong Growth Traits Matching Navellier's Criteria ↗

October 24, 2025

Argenx SE shows strong earnings momentum, soaring revenue growth, and high profitability, aligning with Louis Navellier's systematic growth stock criteria.

Via Chartmill

argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

October 23, 2025

From argenx SE

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.